OPN polymorphism is related to the chemotherapy response and prognosis in advanced NSCLC

Abstract

Background. Osteopontin (OPN) is associated with prognosis of patients with non-small-cell lung cancer (NSCLC). However, little is known about the association between OPN gene polymorphism and the chemotherapy response in NSCLC patients. Methods. A total of 497 patients with inoperable advanced stage of NSCLC (stages III B and IV NSCLC) were enrolled. All patients had received platinum-based chemotherapy. OPN gene polymorphisms at 156 GG/G, 443 C/T, and 66T/G were determined. Results. Thegenotypes and allele frequency of 443C>Twere significantly different between the responders and nonresponders. Responders had a markedly higher frequency of 443TT genotype than responders (40.71% versus 19.09%, p < 0.001).With CC as reference, the TT genotype carriers had a higher chance to be well responders (adjusted OR = 4.43, 95% CI 2.60-7.53, adjusted P < 0.001). The median overall survival time for patients with 443CC, 443CT, and 443TT genotype carriers was significantly different. Multivariate Cox proportional hazards regressionmodels showed that OPN 443C>T gene polymorphisms were closely correlated to poor NSCLC prognosis. Conclusion. OPN 443C>T gene polymorphism may be used as a molecular marker to predict the treatment response to chemotherapy in advanced NSCLC patients.